NEW YORK ( TheStreet) -- Shares of Jazz Pharmaceuticals (Nasdaq: JAZZ) were gapping up Friday morning with an open price 15.3% higher than Thursday's closing price. The stock closed at $45.20 Thursday and opened today's trading at $52.12. The average volume for Jazz has been 966,100 shares per day over the past 30 days. Jazz has a market cap of $2.55 billion and is part of the health care sector and drugs industry. Shares are up 17% year to date as of the close of trading on Thursday. Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, focuses on the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company has a P/E ratio of 17, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Jazz as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Jazz Ratings Report. Get more investment ideas from our investment research center.